Suppliers / Astrazeneca Ab

Astrazeneca Ab

Sweden AZN Updated 9 July 2026

Astrazeneca Ab is an API and finished-dose manufacturer based in Sweden. It holds 3 active US drug master files and one valid CEP across a filed portfolio of 2 molecules. Its filings concentrate with Health Canada, MEDSAFE (NZ) and MPA (SE). Its GMP standing is certified by EMA, MFDS (Korea) and BPOM (ID), among 9 authorities. Its most recent recorded inspection, by US FDA, closed on 27 April 2023 as VAI.

3
active US DMFs
1
valid CEPs
12
registered plants 1 with an FDA FEI number
2,910
filings across 37 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 27 April 2023 VAI US FDA
  • 1 December 2022 VAI US FDA
  • 1 December 2022 VAI US FDA
  • 23 February 2020 VAI US FDA
  • 6 December 2019 VAI US FDA
  • 11 October 2019 VAI US FDA
  • 30 August 2019 VAI US FDA
  • 7 December 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Macclesfield, United Arab Emirates Not on file
Sodertalje, United Arab Emirates Not on file
Baar, Switzerland Not on file
Naucalpan De Juarez, Mexico, Colombia Not on file
United Kingdom, United Kingdom 3002850317
-, Indonesia Not on file

6 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
Health Canada 532 None
MEDSAFE (NZ) 298 None
MPA (SE) 224 None
EMA 210 11
AIFA (IT) 207 None
FAMHP (BE) 152 None
MFDS (Korea) None 10
BPOM (ID) None 8
ANVISA (Brazil) None 7
NCELS (KZ) None 5
NAFDAC (NG) None 4
HSA (SG) None 2
MCAZ (ZW) None 1
EDA (EG) None 1

Scale

Year Revenue Exports Destinations
2024 $1.1B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Astrazeneca Ab comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 84 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 27 April 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported